| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |